We’re thrilled to share that SG Diagnoctics’ PreciSTM-A HbA1c Analysis System has received Therapeutic Goods Administration (TGA) approval in Australia. This approval is far more than a regulatory box ticked. It represents the realization of our vision: delivering accessible and accurate diagnostics testing for anyone, anytime, and anywhere. With TGA approval, our Pont-of-Care test is now ready to support clinicians and healthcare organizations in offering accessible and accurate diabetes monitoring, ultimately empowering patients with better preventive care.
This achievement marks an importance step forward in SG Diagnostics’ mission to improve lives through quality point-of-care diagnosis. We extend our gratitude to our incredible team and partners whose relentless commitment has made this possible, bringing us one step closer to transforming community health across the Asian-Pacific region.
According to the International Diabetes Federation (IDF) 2025 Diabetes Atlas, an estimated 589 million adults aged 20–79 are currently living with diabetes worldwide—about 1 in 9 people. Projections warn this could rise to 853 million by 2050 if stronger action is not taken. Even more concerning is that 252 million of people are living with undiagnosed diabetes, leaving many at risk of preventable complications. Without timely testing and monitoring, the burden on individuals, families, and healthcare systems will continues to grow1.
At SG Diagnostics, we believe that diagnostics can enable healthier futures across the globe. Our journey doesn’t stop here; we’re committed to driving impact and continuing to deliver solutions that make healthcare more accessible.
Learn more about how the PreciSTM-A HbA1c Analysis System is shaping the future of diabetes management here.
Reference:
